<SEC-DOCUMENT>0001493152-19-013908.txt : 20190910
<SEC-HEADER>0001493152-19-013908.hdr.sgml : 20190910
<ACCEPTANCE-DATETIME>20190910075025
ACCESSION NUMBER:		0001493152-19-013908
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190910
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190910
DATE AS OF CHANGE:		20190910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		191084295

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): September 10, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
                                         or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission
    <BR>
    File Number)</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
                                         Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25
                                         Recreation Park Drive, Unit 108</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hingham,
        Massachusetts 02043</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
    of Principal Executive Offices) (Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (781) 875-3605</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
                                         by check mark whether the registrant is an emerging growth company as defined in Rule
                                         405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities
                                         Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; background-color: white; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 31%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.01 par value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBOT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    Capital Market</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
    7.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
    FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2019, Microbot Medical Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that the operational effectiveness
of its Self-Cleaning Shunt (SCS&trade;) was validated in a broader follow-up in-vitro lab study and clearly demonstrated that
the Company&rsquo;s device prevented shunt occlusion under the parameters of that study. Additionally, the press release announced
that the Company remains on target to complete and release the results of the pre-clinical studies to further evaluate the safety
and efficacy of the SCS&trade; being performed at Wayne State University and Washington University School of Medicine in St. Louis,
during the fourth quarter of 2019 and the first quarter of 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be
&ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including
Exhibit 99.1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(d)
Exhibits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 0.9in; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="width: 0.1in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated September 10, 2019</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Harel Gadot</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
September 10, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; padding: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0; padding: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 87px; width: 225px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical&rsquo;s Self-Cleaning Shunt (SCS&trade;) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up In-vitro
Laboratory Study </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Positive
Results Continue to Validate the Operational Effectiveness of the SCS&trade;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HINGHAM,
Mass., September 10, 2019</B> &ndash; Having successfully concluded an independent in-vitro laboratory study and published the
positive results earlier this year, the operational effectiveness of Microbot Medical Inc.&rsquo;s (NASDAQ: MBOT) Self-Cleaning
Shunt (SCS&trade;) was validated in a broader follow-up in-vitro lab study and clearly demonstrated the device&rsquo;s capability
to prevent shunt occlusion under the parameters of that study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
data from this latest study brings us one step closer to commercialization as it continues to demonstrate that Microbot&rsquo;s
SCS&trade; offers a clear competitive differentiation compared with current shunts being used today in thousands of procedures,&rdquo;
commented Harel Gadot, CDEO, President and Chairman. &ldquo;Our SCS&trade; has the potential to yield better patient outcomes,
improve quality of life, positively influence multiple stakeholders and lower healthcare costs.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
follow-up study, which commenced in July 2019 and concluded on August 14, 2019, was conducted by Envigo CRS Israel, a leading
provider of non-clinical contract research services and research models. Human brain glioblastoma cells were used in order to
assess performance of the SCS<SUP>TM</SUP> in a test system with accelerated cell growth rate, accumulation and obstruction rates.
The study demonstrated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    cell growth and accumulation in a non-operating SCS<SUP>TM</SUP> as well as a standard of care surgical shunt.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    significant inhibition in cell growth in daily (5-10 minutes) or weekly (up to 2 hours over the week) operating SCS<SUP>TM
    </SUP>with little cell attachment on the robotic brush (ViRob<SUP>TM</SUP>) and on the opening where the robotic brush (ViRob<SUP>TM</SUP>)
    operates.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    effectiveness of the Company&rsquo;s SCS&trade; devices in preventing cells blockage as compare to standard of care surgical
    shunts</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 39.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company remains on target to complete and release the results of the pre-clinical studies to further evaluate the safety and
efficacy of the SCS&trade; being performed at Wayne State University and Washington University School of Medicine in St. Louis,
during the fourth quarter of 2019 and the first quarter of 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a reminder, Mr. Gadot is presenting at the Rodman &amp; Renshaw Global Investment Conference today at 12:05 pm (ET), at the Lotte
New York Palace in New York City, where he will share the summary results of the follow-up in-vitro laboratory study as well demonstrating
a working headset prototype of the SCS<SUP>TM</SUP> device. A live webcast and subsequent archived replay of the Company&rsquo;s
presentation may be accessed via the &lsquo;Investors&rsquo; section, under &lsquo;Presentations and Resources&rsquo; of the Company&rsquo;s
website at www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Envigo</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Envigo
CRS Israel provides comprehensive scientific expertise and a full service offering in non-clinical research and development, research
models and services, regulatory consulting, and analytical support to our customers. Envigo is a privately held global company
with corporate headquarters in New Jersey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&trade;,
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s
current technological platforms, ViRob<SUP>TM</SUP>, TipCAT<SUP>TM</SUP> and CardioSert<SUP>TM</SUP>, are comprised of three highly
advanced technologies, from which the Company is currently developing its first product candidate: The Self-Cleaning Shunt, or
SCS<SUP>TM</SUP>, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH. The Company also is focused on
the development of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot
Medical is available at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob<SUP>TM</SUP> technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the
body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,
the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRob<SUP>TM</SUP> please visit
http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT<SUP>TM
</SUP>is a transformational self-propelled, flexible, and semi-disposable locomotive device providing see &amp; treat capabilities
within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly
suitable to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve
the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT<SUP>TM</SUP>,
visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CardioSert<SUP>TM
</SUP>technology contemplates a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal
surgery. The CardioSert<SUP>TM</SUP> technology features unique steering and stiffness control capabilities, and it was originally
developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during
percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as
peripheral intervention, neurosurgery and urology. CardioSert<SUP>TM</SUP> was part of a technological incubator supported by
the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully
completed pre-clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and the Federal securities laws.. Any statements that are not historical fact (including, but not
limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization
of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty
in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated
in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses
of Microbot Medical Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&rsquo;s filings
with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 5P#A P$1  (1 0,1 ?_$ +T  0 # 0$  P$!
M       '" D*!@$"!00# 0$  @(# 0$              0(#! 8'" D%$
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M'V^86+.6\2CI_J[3R7C&#,R,IYR!B=;<:4,M2N2OXMV$[K4=Q"^?Q7EDA_\
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M%I5;@O?.?AN?T\GUXO*3"<: @-]IR#Y6[0,:D [.9N''ZA8V8((ANJ<Y9=H
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M[@%XV$.9E-E\UY9R'<JQC\T](URBUBFO/IK^4:02QV3F8F94Q5')R*NB&!%
M@E33( =-Q$=89)G@EC<E<-J*JT7(3%=,\8V&YRAX=L=EGY[D!.OYN;E;@Z3?
MR98BJL(R,CX07)")&6BEI&40.NF;JL@W.D;<JA@&8RZ4^?(*SL LD,(X3R7R
M\SY!8CK%B7C)FR-GULR!D62)]3?05:9KIH.73<CCN*M*2#E3TT -NDB4H]I>
M@!J\KRQOEZJ@%31;16[P:T%A271\9YGR.&2&;!5=DYN+Y*8K,W)))"8K23C!
M2*+1J[4#L[T!(=+NW#X;:PMGD&>*M[;<QFL(VDC>L66XLC$/'M/R+0)Q[[5P
MS7.16)L,&[<,GS-02[%>QKIPU4;N$3@*3EL<2G*(#MK<J2#C@10^(Z_/ZX+$
M0/@#0U_I3$'Q&*TKY@16*ISCGQKY2XMI4%2IS.C61')-2CVQD*',2K&&2=R3
MA&MMS$;5Z8&8!3=Y&@W,8O\ K"*#UUYPYK]N?&>2[@>3<+N)N,\\B=JBO+*L
M;2^M1[T;" 6DYEE"<=0<,%W_ ,)^X#DO'=N_VWRZWAY'P=XTOM+RCW-;E_!D
M?6C@,@^HK326'%9NU6J5/)=SKM6?9#5PU77LQ'%OLM(1CJR.JY"O#J)MGM>>
MMTA8NTW+Q,2%.X3!RB4!,5,XE'7&+#O1W![4W3-@^X2Q+MH)#8=^LV:[=]<!
M^<C8*1N)S>QK'#-T5,5R?<.T/ ^YUF_?^P5Z!N3&ZIMBNW:+EG4_E'O-9&@9
M,>YS2<&2#);8V/PN8NE<6!;./F=;C8K4I"GE8)_8YMI:*;<UR(&63;./0 19
MD?G(*8*('*9$X]0Z"77IO:]YL]XL8MSVN>*YVZ9H=')&X/8]IR+7MJ#],C@5
MYIW';+_:;V7;=SAEM]Q@>6R1R-+'L<,PYKJ$?\,0L/8FPW7%MFCK=7'3NKY
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M:BRJ6]$51^>7\'O(']W[[^MLM9(OQ!\U5WI7'15O^*&*-P 0'-&.=P'X#_\
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M_+WC5CB=+6[OF2E5Z7,J")FSR1$Q$3B<$]G#E!-5N@!3F #&,8"D_2$.NNW
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J"]ICI8'_ *CL6GYG3J3A86[GU!7],' %-OW@7X#JOS4X?56 T1-$7__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
